RxDoctor Payments Data

Edward Scanlan, MD

Internal Medicine · Brandon, FLNPI 1861475196

Payments from drug & device makers

$2,082in general payments, 2019–2025

Across 143 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$675
  • Amarin Pharma, Inc.$272
  • Novo Nordisk$249
  • Amgen$195
  • Johnson & Johnson$113
  • Boehringer Ingelheim$112
  • plus $466 from 10 others

What the payments were for

  • Food & beverage$2,07099%
  • Education$111%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,082 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$75,544
Medicare patients
280
Services billed
2,538

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide76$98,647
JardianceEmpagliflozin53$56,833
OzempicSemaglutide30$47,091
FarxigaDapagliflozin Propanediol35$43,283
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$42,363
XareltoRivaroxaban29$40,885
EliquisApixaban38$35,060
MounjaroTirzepatide14$17,992
VascepaIcosapent Ethyl12$8,823
Tresiba Flextouch U-200Insulin Degludec16$8,012
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$4,407
EdarbiAzilsartan Medoxomil17$4,368
Levothyroxine Sodium310$3,047
Atorvastatin Calcium355$2,585
Olmesartan Medoxomil104$2,445

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$83$116,63990 claims
Boehringer IngelheimJardiance$112$56,83353 claims
Novo NordiskOzempic$249$47,09130 claims
AstraZenecaFarxiga$675$43,28335 claims
GSKTrelegy Ellipta$106$42,36341 claims
Johnson & JohnsonXarelto$113$40,88529 claims
PfizerEliquis$27$35,06038 claims
Arbor Pharmaceuticals, Inc.Edarbi$19$4,36817 claims
AbbVieSynthroid$93$1,64822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →